Cross-Appointed Member, Assistant Professor, Pathology and Laboratory Medicine, University of Ottawa and Clinical Biochemist, The Ottawa Hospital/EORLA, Laboratory Director, Pembroke Regional Hospital
Dr. Colantonio completed his undergraduate and PhD (Physiology 2004) degrees from Queen’s University, Kingston. Following his graduate studies he completed a clinical postdoctoral fellowship in Clinical Biochemistry at John’s Hopkins University, School of Medicine, Baltimore (2006). Dr. Colantonio is certified as a specialist in Clinical Chemistry and is a fellow of both the Canadian Academy of Clinical Biochemists and the American Academy of Clinical Chemists. He is currently an Assistant Professor in the Department of Pathology and Laboratory Medicine and a Clinical Biochemist at the Ottawa Hospital where he directs the HPLC lab and porphyrin testing. His specialty is in therapeutic drug monitoring and toxicology; he is currently in the process of setting up a clinical therapeutic drug monitoring and toxicology lab using mass spectrometry.
In addition to his work in laboratory medicine, Dr. Colantonio has extensive experience teaching, supervising graduate students and conducting research. His research is in the area of therapeutic drug monitoring and pharmacokinetics. Dr. Colantonio is a member of the DLAC (Drugs in Lactation) research group based at the Hospital for Sick Kids in Toronto, where he spent the last 10 years working as a clinical biochemist and conducting research at the University of Toronto. His research focuses on investigating the excretion of drugs into breast milk and assessing the potential risk it may pose to nursing infants. The first step in assessing drug safety during breastfeeding is to measure drug concentrations in breast milk; this is accomplished by developing analytical methods to measure drug concentrations with mass spectrometry. These drug concentrations are then modeled, using population PK analyses (Non-linear Mixed Effects Modeling), to determine how much drug an infant would ingest, and consequently, assess the risk of drug exposure to the nursing infant.
- Delaney SR, Edginton A, Colantonio DA, Ito S. Development of a Physiologically-Based Pharmacokinetic Model to Predict Escitalopram Plasma Exposure in Breast-Feeding Infants. Clin Pharmacokinets, 2018 Apr 12
- Raizman JE, Taylor K, Parshuram C, Colantonio DA. Milrinone Therapeutic Drug Monitoring in a Pediatric Population: Development and Validation of a Quantitative Liquid Chromatography-Tandem Mass Spectrometry Method Clinica Chimica Acta 468 (2017), p.71-75
- Lau E, Brophy J, Samson L, Kakkar F, Campbell D, Yudin MH, Murphy K, Seto W, Colantonio DA, Read SE, Bitnun A. Nevirapine Pharmacokinetics and Safety in Neonates Receiving Combination Antiretroviral Therapy for Prevention of Vertical HIV Transmission. Journal of Acquired Immune Defic Synd, 2017 Apr 15;74(5):493-498.
- Neuman G, Colantonio DA, Szynkaruk M, Shinya Ito. Bupropion and Escitalopram During Lactation: a case report and review of the literature. Ann Pharmacother. 2014 Apr 14;48(7):928-931.4
- Neuman G, Nulman I, Adeli K, Koren G, Colantonio DA, Helldén A. Implications of Serum Creatinine Measurements on GFR estimation and Vancomycin Dosing in Children. J J Clin Pharmacol. 2014 Jul;54(7):785-91
- Bailey D, Bevilacqua V, Colantonio DA, Pasic MD, Perumal N, Khun Chan M, Adeli K. Pediatric Within-Day Biological Variation and Quality Specifications for 38 Biochemical Markers in the CALIPER Cohort. Clin Chem. 2014 Mar;60(3):518-29.
- Tanoshima R, Chandranipapongse W, Colantonio D, Stefan C, Nulman I. Acute olanzapine overdose in a toddler: a case report. Ther Drug Monit. 2013 Oct;35(5):557-9.
- Shaw JL, Binesh Marvasti T, Colantonio D, Adeli K. Pediatric reference intervals: challenges and recent initiatives. Review Crit Rev Clin Lab Sci. 2013 Feb-Apr;50(2):37-50.
- Colantonio DA, Kyriakopoulou L, Chan MK, Daly CH, Brinc D, Venner AA, Pasic MD, Armbruster D, Adeli K. Closing the gaps in pediatric laboratory reference intervals: a CALIPER database of 40 biochemical markers in a healthy and multiethnic population of children. Clin Chem. 2012 May;58(5):854-68.
- Chen J, Chan C, Colantonio DA, Seto W. Therapeutic drug monitoring of voriconazole in children. Ther Drug Monit. 2012 Feb;34(1):77-84. Review.